Daily Stock Analysis, BPTH, Bio Path Holdings Inc, priceseries

Bio Path Holdings Inc. Daily Stock Analysis
Stock Information
Open
1.00
Close
0.95
High
1.00
Low
0.91
Previous Close
0.95
Daily Price Gain
0.00
YTD High
1.35
YTD High Date
Jan 3, 2017
YTD Low
0.81
YTD Low Date
Feb 3, 2017
YTD Price Change
-0.30
YTD Gain
-24.00%
52 Week High
3.19
52 Week High Date
Apr 5, 2016
52 Week Low
0.81
52 Week Low Date
Feb 3, 2017
52 Week Price Change
-0.60
52 Week Gain
-38.71%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Sep 29. 2015
1.09
Nov 2. 2015
1.45
24 Trading Days
32.89%
Link
LONG
Nov 30. 2015
1.58
Dec 9. 2015
1.70
7 Trading Days
7.88%
Link
LONG
Feb 16. 2016
1.40
Mar 4. 2016
1.69
13 Trading Days
21.06%
Link
LONG
Mar 24. 2016
2.12
Apr 22. 2016
2.69
20 Trading Days
27.01%
Link
LONG
Nov 4. 2016
1.07
Nov 17. 2016
1.24
9 Trading Days
15.50%
Link
Company Information
Stock Symbol
BPTH
Exchange
NasdaqCM
Company URL
http://www.biopathholdings.com
Company Phone
(832) 742-1357
CEO
Peter H. Nielsen
Headquarters
Texas
Business Address
4710 BELLAIRE BOULEVARD, SUITE 210, BELLAIRE, TX 77401
Sector
Equity
Industry Category
Drugs
Industry Group
Drug Delivery
CIK
0001133818
About

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused antisense drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-e...

Description

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused antisense drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is Liposomal Grb2, which is in Phase II clinical trials for the treatment of acute myeloid leukemia and chronic myelogenous leukemia; and in preclinical studies for solid tumors, including triple negative breast cancer and inflammatory breast cancer. The company is also developing Liposomal Bcl2, which is in Phase I clinical trial for the treatment of lymphoma. It has license agreement with The University of Texas relating to the delivery technology platform for antisense nucleic acids, including two single nucleic acid drug products. The company was founded in 2007 and is based in Bellaire, Texas.